No birth defect pattern has been reported in humans exposed to semaglutide during pregnancy, but the number of documented exposures remains small
This initiative is timely: the global market for GLP-1 obesity and diabetes drugs is exploding (projected ~USD 62 billion in 2025 to ~USD 157 billion by 2035 ( [7] ), with forecasts of ~$200 billion by 2030 ( [8] ) and tens of millions of patients on GLP-1s by the end of the decade)
Fat cells release inflammatory mediators known as adipokines , including: Leptin Adiponectin Interleukin-6 Tumor necrosis factor-alpha These mediators contribute to: Cartilage degradation Synovial inflammation Osteophyte formation Because of these mechanisms, obesity is considered one of the most important modifiable risk factors for knee osteoarthritis
Kao D, Roach B, Silva M, Beck P, Rioux K, Kaplan GG, et al
In the new substudy, once weekly semaglutide (1 mg) was shown to reduce the risk of time to first composite HF event (new onset or worsening HF leading to unscheduled hospital admission or urgent visit, with initiation of or intensified diuretic/vasoactive therapy) or cardiovascular death and HF events and cardiovascular death alone
How to set a weight-loss goal A realistic weight-loss goal has three parts: how much, how fast, and how you will hold the deficit